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Identifying direct substrates of mitogen-activated protein kinases (MAPKs) and understanding how those
substrates are selected is central to understanding how these ubiquitously activated enzymes generate diverse
biological responses. In previous work, we identified several new candidate substrates for the MAPK ERK2
(extracellular signal-regulated kinase 2), including the nuclear pore complex protein Tpr (translocated pro-
moter region). In this report, we identify sites on Tpr for ERK2 phosphorylation and binding and demonstrate
their functional interaction. ERK2 phosphorylation and dimerization are necessary for ERK2-Tpr binding,
and this occurs through a DEF (docking site for ERK2, FXF) domain on Tpr. Surprisingly, the DEF domain
and the phosphorylation sites displayed positive cooperativity to promote ERK2 binding to Tpr, in contrast to
substrates where phosphorylation reduces binding. Ectopic expression or depletion of Tpr resulted in de-
creased movement of activated ERK2 from the cytoplasm to the nucleus, implying a role for Tpr in ERK2
translocation. Collectively, the data provide direct evidence that a component of the nuclear pore complex is
a bona fide substrate of ERK2 in vivo and that activated ERK2 stably associates with this substrate after
phosphorylation, where it could play a continuing role in nuclear pore function. We propose that Tpr is both
a substrate and a scaffold for activated ERKs.
The mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) pathway regulates many cel-
lular processes, including proliferation, differentiation, tran-
scription, and cellular motility (28). MAPKs are activated via a
kinase cascade that results in their dual phosphorylation on
tyrosine and threonine and their consequent activation (6).
Although a great deal is known about the biochemical steps
involved in the transduction of signals through this pathway,
considerably less is known about how these signals are con-
verted into specific biological responses. Understanding this
process of signal implementation will require identification of
the in vivo substrates of the MAPKs. Although over 150 pos-
sible ERK substrates have been reported (49), in very few
cases has it been demonstrated that these proteins are in vivo
substrates and that MAPK is directly responsible for the phos-
phorylation.
In the inactive state the ERKs are anchored in the cytoplasm
by their association with the MAPK/ERK kinases (MEKs) and
several other proteins. Upon activation, the ERKs are released
from their anchor and migrate to the nucleus, where they
phosphorylate several transcription factors (such as Ets fac-
tors) and play an important role in transcriptional regulation
(5, 7, 12, 18, 22, 45). Nuclear localization of ERKs can be
brought about by either passive diffusion of monomers or ac-
tive transport (1). Interaction with nucleoporins such as
Nup153 and Nup214 has also been suggested to play a role in
localization of ERK2 to the nucleus (26, 46), but virtually
nothing is known about the ERK partners and substrates that
might play a role in this process or in aspects of posttranscrip-
tional gene regulation.
Once at their sites of action, ERKs recognize and phosphor-
ylate serine or threonine residues in the sequence context of
S/TP or PXS/TP (17). However, the specificity of the interac-
tion and phosphorylation comes also from docking motifs on
the substrates. Two different kinds of domains or motifs have
been identified on candidate ERK substrates. The first is a
KIM (kinase-interacting motif, also known as a D domain)
which consists of a stretch of basic amino acids surrounded by
aliphatic hydrophobic residues (leucines, isoleucines, or va-
lines) (3, 38, 42, 50). The second is a DEF domain (docking site
for ERK, FXF) consisting of two phenylalanine residues sep-
arated by one residue, followed by a proline (FXFP), although
the proline residue is not essential (11, 15, 21, 43).
To understand the functions of the pathway, identifying and
characterizing the direct in vivo targets of ERK phosphoryla-
tion and analyzing the molecular basis for substrate specificity
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are of primary importance. In a previous report (10), we iden-
tified candidate ERK substrates in cell lysates using a method
developed by Shokat and colleagues, in which a structural
“pocket” is engineered into protein kinases so that they can
utilize ATP orthologs that have bulky substituents (37). In
addition to the known ERK2 substrate Rsk2, two novel sub-
strates, E3 ubiquitin ligase EDD (E3 identified by differential
display) and nuclear pore complex protein Tpr (translocated
promoter region), were found to associate with and be phos-
phorylated by the ERK2 pocket mutant.
Tpr was originally identified by its fusion (short fragments of
Tpr) to various proto-oncogenes such as met and raf (19, 23,
29). Tpr localizes to the nuclear basket of the nuclear pore
complex and is also found in the nucleus in the form of discrete
foci (14). The functions of Tpr are poorly understood, but
several lines of evidence indicate that it is involved in the
process of nuclear export. Tpr has been shown to have a role
in the nuclear export of proteins containing a leucine-rich
nuclear export signal (14) and in the nuclear export of Hun-
tingtin, a protein with no obvious nuclear export signal (8).
Ectopic expression of mammalian Tpr has also been reported
to result in accumulation of poly(A) RNA in the nucleus (2).
In this report, we characterize Tpr-ERK2 interactions and
phosphorylation of Tpr by ERK2 in vitro and in vivo. We
identify structural elements in Tpr and ERK2 important for
Tpr and ERK association. ERK2 interacts with Tpr through
positive cooperative interactions of DEF and the ERK phos-
phorylation sites. This is in contrast to the other ERK sub-
strates identified with the “pocket mutant” technique, which
display decreased binding following phosphorylation. Because
phosphorylation of Tpr by activated ERK stabilizes their in-
teraction, we hypothesize that this phosphorylation is not part
of a signal amplification cascade but rather positions activated
ERK to perform a continuing function in the nuclear pore. We
also show that depletion of Tpr results in decreased nuclear
accumulation of activated ERK2, suggesting a role for Tpr in
modulating ERK2 translocation into the nucleus.
MATERIALS AND METHODS
Reagents, constructs, and mutagenesis. COS-1 cells were from the American
Type Culture Collection (ATCC, Manassas, VA) and were maintained in Dul-
becco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) with 5% fetal
bovine serum (Invitrogen). Anti-FLAG-M2 monoclonal antibodies and anti-
FLAG-M2 agarose affinity beads were from Sigma (St. Louis, MO). Monoclonal
anti-hemagglutinin (HA) antiserum 12CA5 was purchased from Covance, Berke-
ley, CA. Constructs of Tpr antibodies (raised against amino acid residues 2095 to
2348), full-length Tpr fused to enhanced green fluorescent protein (EGFP-Tpr),
and the C-terminal portion of Tpr fused to HA epitope (HA-TprC; amino acids
1626 to 2340) were kindly provided by L. Gerace (The Scripps Research Insti-
tute, La Jolla, CA) (2, 14). The FLAG-ERK2 construct has been previously
described (40). FLAG-ERK2-T183AY185F (TAYF) and FLAG-ERK2-K52R
constructs were generated by PCR mutagenesis. The ERK2-4 mutant was a gift
from M. H. Cobb, University of Texas Southwestern Medical Center, Dallas, TX
(32). ERK2-4 was subcloned into FLAG-ERK2 to generate FLAG-ERK2-4.
The JNK1 construct was provided by Roger Davis, University of Massachu-
setts Medical School, Boston, MA (9), and the GST-p38 construct was provided
by Dennis J. Templeton, University of Virginia, VA (36). pcDNA3-FLAG-JNK1
and pcDNA3-FLAG-p38 constructs were generated by amplifying JNK1 and
p38 coding regions by PCR and subcloning the products into pcDNA3-FLAG
vector. FLAG-tagged Tpr C-terminal (FLAG-TprC; amino acids 1626 to 2349)
and FLAG-tagged Tpr N-terminal (FLAG-TprN; amino acids 1 to 800) con-
structs were generated by PCR amplification of the respective regions using
EGFP-TprFL (14) as a template. PCR products were digested with NotI and
ApaI (introduced through primers) and subcloned into the same sites in
pcDNA3-FLAG vector. FLAG-tagged full-length Tpr (TprFL) was generated by
ligating the NotI-BmtI fragment from FLAG-TprN and the BmtI-PpuMI frag-
ment from pGFP-Tpr and subcloning into NotI-PpuMI sites of FLAG-TprC
vector. FLAG-ERK2-DD3NN, FLAG-ERK2 L232A, and various FLAG-TprC
mutants were generated by PCR mutagenesis.
Immunoprecipitation. Dishes (100 mm) of COS-1 cells (2.4  106 to 3  106
cells) were transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s recommendations. Cells were allowed to recover overnight, and
transfected cells were then serum starved for 4 to 5 h and stimulated either with
epidermal growth factor (EGF) (20 ng/ml) for 10 min or with anisomycin (1 M)
for 30 min. Immunoprecipitation was carried out as described previously (10).
In vitro kinase reactions and phosphoamino acid and phosphopeptide anal-
ysis. After transfection and immunoprecipitation as described above, the immu-
noprecipitated FLAG-TprFL, FLAG-TprC, and mutants of FLAG-TprC or the
vector control were mixed with immunoprecipitated ERK2, and kinase reactions
were performed in 25 mM HEPES (pH 7.4), 20 mM magnesium acetate, and 1
mM dithiothreitol containing 10 Ci [-32P]ATP (Perkin Elmer, Boston, MA),
for 10 min at 30°C. Phosphoamino acid and tryptic peptide analysis were per-
formed as described previously (4, 10).
Metabolic labeling and phosphopeptide analysis. Dishes (100 mm) of COS-1
cells were transfected with 10 g of FLAG-Tpr constructs and were allowed to
recover overnight. Cells were washed twice with phosphate-free RPMI medium
and starved for 1 h in phosphate-free RPMI medium (Invitrogen). Cultures were
metabolically labeled in phosphate-free RPMI medium containing 3 mCi/ml
carrier-free 32Pi (Perkin Elmer) for 3 h. For EGF-stimulated samples, EGF (20
ng/ml for 10 min) was added to the above medium. Cultures treated with the
MEK inhibitor UO126 (Calbiochem, La Jolla, CA) were incubated with 20 M
inhibitor during the 3-h labeling and the EGF stimulation. Immunoprecipitation
and tryptic peptide analysis were performed as described previously (10).
Immunoprecipitations, kinase assays, and two-dimensional gel electrophoresis.
32P-labeling of cyclopentyl ADP (cpADP) was carried out as described previ-
ously (10). Two 150-mm dishes of COS-1 cells (5  106 cells) were cotransfected
with 6 g of HA-ERK2 or HA-ERK2-QG and 12 g of pcDNA3 or FLAG-
TprFL or FLAG-TprFL-FXF3AXA,M4 and were allowed to recover overnight.
Transfected cells were then serum starved for 4 to 5 h and stimulated with EGF
(20 ng/ml) for 10 min. Immunoprecipitation, kinase assay, and two-dimensional
gel electrophoresis were essentially performed as described previously (10).
Ectopic expression, siRNA attenuation of Tpr, and dynamic analysis of ERK
in HEK293T cells. A double-stranded small interfering RNA (siRNA) targeting
5 GCACAACAGGATAAGGTTA 3 of the Tpr gene was purchased from
Qiagen Inc. (Valencia, CA). The control siRNA duplex pool (nonspecific control
duplex XIII) was purchased from Dharmacon (Lafayette, CO). HEK293T cells
were plated in media containing 10% serum on 10 g/ml fibronectin on 5 g/ml
collagen type IV-coated tissue culture dishes. The following day, cells were
transfected using Polyfect reagent (for plasmid constructs) (Qiagen) or calcium
phosphate (for siRNA) with 400 ng cyan fluorescent protein (CFP)-MEK1, 400
ng yellow fluorescent protein (YFP)-ERK, and 1 g of pcDNA3 or 1 g FLAG-
TprFL or with control siRNA or Tpr siRNA. Twenty-four hours posttransfec-
tion, cells were serum starved for 3 h and stimulated with EGF (10 ng/ml). The
cellular dynamics of YFP-ERK2 and CFP-MEK were captured using a Nikon
Eclipse TE2000-E inverted microscope. To quantify YFP-ERK recruitment into
the nucleus, the fluorescent intensity of nuclear YFP-ERK was divided by the
total intensity (cytoplasmic plus nuclear intensity) of YFP-ERK plus CFP-MEK
(YFP/CFP  YFP). Image analysis was performed using Image J software
(Wayne Rasband, National Institutes of Health).
Immunofluorescence. Dishes (60 mm) of COS-1 cells (6  105 cells) were
transfected with 1.5 g of GFP-Tpr constructs using Lipofectamine 2000. Cells
were trypsinized and plated on coverslips in a six-well dish 24 h after transfection
and allowed to recover for 48 h. Cells were washed twice with phosphate-
buffered saline and fixed with 3% paraformaldehyde for 20 min followed by
extraction with cold methanol for 5 min at 20°C. Coverslips were mounted on
slides using Vectashield mounting medium (Vector, Burlingame, CA), and cells
were examined under a confocal microscope (Zeiss LSM 510 microscope; Uni-
versity of Virginia Advanced Microscopy Facility).
RESULTS
The carboxy terminus of Tpr is sufficient for interaction with
activated ERK2. To characterize the ERK2-Tpr interaction,
FLAG-ERK2 or the ERK2 “pocket” mutant ERK2-Q103G
(ERK2-QG), which can utilize analog ATP as the substrate,
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was immunoprecipitated and the immunocomplexes were
probed with anti-Tpr antibodies. The association of endoge-
nous Tpr with ERK2 or ERK2-QG in serum-starved cells was
weak but increased following EGF stimulation (Fig. 1A). Anal-
ysis of the primary sequence of Tpr revealed the presence of a
putative KIM (or D domain) and a putative DEF motif in the
C-terminal 800-amino-acid region that could be involved in its
association with ERK2. Like full-length Tpr (Fig. 1A), HA-
TprC (C-terminal fragment) interacted strongly with FLAG-
ERK2 when cells were stimulated with EGF (Fig. 1B). In a
reverse experiment, HA-TprC was immunoprecipitated and
the FLAG-ERK2 interaction with Tpr was examined. A robust
association of FLAG-ERK2 with HA-Tpr was evident in EGF-
stimulated cells (Fig. 1C). These results indicate that Tpr as-
sociates strongly with ERK2 following EGF stimulation, and
the C-terminal 800 amino acids of Tpr are sufficient for this
interaction.
Tpr does not interact with MEK1, JNK1, or p38. To test
the specificity of the interaction of Tpr with ERK2, we exam-
ined possible associations of Tpr with other MAPK pathway
proteins as well. Endogenous Tpr associated strongly with
ERK2, ERK2-QG, and ERK1, following stimulation with EGF
(Fig. 2A). We also detected the association of Tpr with ERK2
and ERK1 in unstimulated reactions, albeit at much lower
FIG. 1. Carboxy terminus of Tpr is sufficient for association with
ERK2 upon EGF stimulation. (A) Cells transfected with pcDNA3,
FLAG-ERK2, and FLAG-ERK2-QG were serum starved for 4 to 5 h
followed by stimulation with EGF (20 ng/ml) for 10 min. Cells were
lysed and proteins immunoprecipitated (IP) with FLAG-M2 agarose
beads. Immunoprecipitated proteins were resolved by 10% SDS-
PAGE, followed by immunoblotting with anti-FLAG-M2 or anti-Tpr
antibodies. (B) Cells transfected with pcDNA3, HA-TprC, FLAG-
ERK2, or FLAG-ERK2 and HA-TprC together were serum starved
and stimulated with EGF. Proteins were immunoprecipitated and an-
alyzed by immunoblotting as described for panel A and probed with
anti-FLAG-M2 and anti-HA antibodies. (C) As in panel B, except that
the proteins were immunoprecipitated with anti-HA antibodies cou-
pled to protein A agarose, followed by immunoblotting with anti-
FLAG-M2 and anti-HA antibodies.
FIG. 2. Tpr does not interact with MEK1, JNK1, or p38. (A) Cells
transfected with pcDNA3, FLAG-ERK2, FLAG-ERK2-QG, FLAG-
ERK1, and FLAG-MEK1 were serum starved and stimulated with EGF.
Cells were lysed and proteins immunoprecipitated (IP) with FLAG-M2
agarose beads followed by immunoblotting with anti-Tpr and anti-
FLAG-M2 antibodies. (B) Cells were transfected with pcDNA3 or HA-
TprC, or double transfected with HA-TprC and FLAG-ERK2 or FLAG-
JNK1 or FLAG-p38. The last two were stimulated with anisomycin for
30 min instead of EGF. Cell lysates were probed with anti-FLAG-M2 and
anti-HA antibodies. Based on these results, twice the amount of lysate was
used for immunoprecipitation from cells cotransfected with FLAG-JNK1
and HA-TprC, compared to amounts for other transfected cells. Proteins
were immunoprecipitated with FLAG-M2 agarose beads. One-twentieth
of the immunoprecipitated proteins was analyzed by probing with anti-
FLAG-M2, anti-phosphor-ERK2 (Sigma), anti-phosphor-JNK1 (Sigma),
and anti-phospho-p38 (Sigma). The remaining immunoprecipitated pro-
teins were probed with anti-HA antibodies.
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levels (Fig. 2A). A possible reason for this is the presence of
low levels of activated ERKs in these cells even during serum
starvation. No interaction between Tpr and MEK1 (Fig. 2A)
was detected. These results suggest that the interaction of Tpr
with ERK2 and ERK1 is specific and most likely requires
activated ERKs. To examine Tpr interactions with JNK1 and
p38, we coexpressed HA-TprC and FLAG-tagged ERK2,
JNK1, or p38. It was evident from the lysate analysis (Fig. 2B)
that expression levels of FLAG-JNK1 and HA-TprC in JNK-
TprC-cotransfected cells were 	2- to 3-fold lower than the
expression levels of ERK2 and p38 and the corresponding
HA-TprC levels. To compensate for the lower expression of
JNK and TprC, twofold more lysate was used in immunopre-
cipitations. Results obtained with phospho-antibodies demon-
strated efficient activation of MAPKs following stimulation
(Fig. 2B). No associations between HA-TprC and MAPKs
JNK1 and p38 were observed, irrespective of the activation
statuses of these two kinases (Fig. 2B). These data demon-
strate that Tpr interacts specifically with the ERKs and not
with MEK1, JNK1, and p38.
ERK2 phosphorylates serine and threonine residues of Tpr
in vitro. The primary sequence of Tpr contains 20 ERK2 con-
sensus sequence target sites: one SP and two TP sites within the
N-terminal 1,600 amino acids, and 3 SP and 14 TP sites within the
C-terminal 800 amino acids. Since the C-terminal 800 amino acids
are sufficient for interaction with ERK2, we tested this fragment
for possible in vitro phosphorylation. Results demonstrated phos-
phorylation of FLAG-TprC by ERK2 (Fig. 3A). TprC phosphor-
ylation by ERK2 was evident, and it was more efficient than that
of the canonical in vitro substrate myelin basic protein (data not
shown). Phosphoamino acid analysis showed phosphorylation of
both serine and threonine residues (Fig. 3B), and thus we could
not rule out any of the 17 putative target sites. Two-dimensional
tryptic phosphopeptide maps of in vitro-phosphorylated Tpr (Fig.
3C) showed that the bulk of the phosphorylation was concen-
trated in two spots and minor phosphorylation was apparent in
four other spots. A similar experiment performed with FLAG-
TprN (N-terminal 800 amino acids containing the remaining
three target sites) showed that TprN was not phosphorylated by
ERK2 in vitro (data not shown). To further confirm that the
N-terminal domain of Tpr is not phosphorylated by ERK2, we
compared the peptide maps for in vitro-labeled full-length Tpr
(TprFL) with that of the C-terminal domain of Tpr (TprC). Two-
dimensional tryptic phosphopeptide maps of in vitro-phosphory-
lated TprFL and TprC showed similar patterns (Fig. 4A), sug-
gesting that TprFL and TprC were phosphorylated on the same
sites.
Tpr is phosphorylated by ERK2 at four different sites. We
mutagenized all 17 putative target sites individually from
serine or threonine to alanine, to determine which sites would
alter the two-dimensional tryptic phosphopeptide maps. Thir-
teen of the seventeen mutants had the same pattern of tryptic
phosphopeptides as TprC (data not shown). Four mutants
(T2102A, T2123A, S2141A, and T2200A) displayed altered
maps (Fig. 4A). Mutation in T2123 resulted in the loss of two
spots that were numbered 4 and 4*. The presence of two spots
for a monophosphorylated peptide could be due to incomplete
digestion by trypsin. Four combination target site mutants
were made. These included one with both major sites mutated
(Fig. 4B, top panel; TprCM2), a second with the two major
sites and one minor site T2200 mutated (TprC16M3), a third
where the major sites and the minor site T2102 were mutated
(TprC12M3), and a fourth where all four phosphorylation sites
were mutated (TprC-M4). The phosphopeptide maps of in
vitro-phosphorylated TprC and Tpr combination mutants (Fig.
4B, lower panel) demonstrated the absence of phosphorylation
on major and minor peptides. These maps also showed in-
creased phosphorylation of other sites, which likely represents
hyperphosphorylation of the remaining minor sites. Most im-
portantly, the TprC-M4 peptide map demonstrated the com-
plete disappearance of ERK2-mediated phosphorylation. In-
corporation of 32P into TprC, TprC-M4, and the control was
quantified by Cerenkov counting (Fig. 4C) and plotted as the
percentage counts calculated with respect to counts in TprC
(fixed at 100%). Mutating all four sites decreased the phos-
phorylation of Tpr by 	90% (Fig. 4C). Based on these results,
we conclude that Thr2123 and Ser2141 are the major ERK2-
mediated phosphorylation sites and Thr2102 and Thr2200 are
minor ERK2-mediated phosphorylation sites on Tpr in vitro.
ERK2 phosphorylates Tpr at the same sites in vivo and in
vitro. To determine if the same Tpr sites are utilized by ERK2
in vivo and in vitro, cells transfected with FLAG-TprFL and
FLAG-TprC were metabolically labeled with 32Pi with or with-
out EGF stimulation. We observed a reproducible 	1.3-fold
increase in levels of phosphorylation upon EGF stimulation
(data not shown). Blocking the ERK activation with MEK
inhibitor UO126 resulted in an 	50% decrease in phosphory-
lation levels of TprFL and TprC compared to levels in EGF-
stimulated samples (data not shown). Tryptic peptide maps
obtained for TprC with and without EGF stimulation were
similar except for a slight increase in the intensity of spots (Fig.
5A). This is in keeping with earlier results where some inter-
action of Tpr with ERK2 was detected even in non-EGF-
FIG. 3. ERK2 phosphorylates serine and threonine residues of Tpr
in vitro. (A) Cells were transfected individually with FLAG-ERK2,
FLAG-TprC, and pcDNA3 vectors. Cells were serum starved, and
FLAG-ERK2-transfected cells were stimulated with EGF. Proteins
were immunoprecipitated from lysed cells with FLAG-M2 agarose
beads, and FLAG-ERK2 immunoprecipitate was mixed either with
FLAG-TprC immunoprecipitate or with immunoprecipitate from
pcDNA3-transfected cells. Kinase reactions were carried out with
[-32P]ATP at 30°C for 10 min. (B) Phosphoamino acid analysis of in
vitro-labeled TprC from time course reactions. p, phosphorylated.
(C) In vitro phosphorylated TprC was digested with trypsin, and the
resulting phosphopeptides were mapped by two-dimensional TLC (4).
Two major spots are indicated by white arrows, and four minor spots
are indicated by black arrows.
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stimulated cells (Fig. 1 and 2), which is possibly due to the fact
that serum starvation does not completely eliminate activated
ERK from these cells. Pretreatment of cells with the MEK
inhibitor UO126 abolished the emergence of the tryptic pep-
tides numbered 1, 2, 3, 4, and 4*, demonstrating that phosphor-
ylation on these peptides depends on activation of ERK. In
addition, we also detected tryptic peptides that are not affected
by EGF treatment or UO126 pretreatment (Fig. 5A). These
most likely arise from phosphorylation by other cellular ki-
nases. In vivo-labeled full-length Tpr (TprFL) and C-terminal
Tpr fragment (TprC) peptide maps were almost identical, sug-
gesting that all the ERK-dependent and -independent phos-
phorylations are in the C-terminal 800 amino acids of Tpr.
Comparison of the tryptic peptide maps of in vivo- and in
vitro-labeled Tpr (Fig. 5A) showed that peptides which disap-
pear upon UO126 pretreatment migrate at the same position
on the thin-layer chromatography (TLC) plates as the in vitro
phosphorylated peptides, indicating that these peptides were
likely phosphorylated by ERK2.
To conclusively prove that the UO126-sensitive tryptic pep-
tides detected with in vivo labeling were actually the same
peptides detected in an in vitro kinase reaction, we performed
another in vivo labeling experiment with TprC and TprC-M4.
We observed that total phosphorylation levels of TprC in
UO126-treated cells, as well as of TprC-M4, were 50% lower
than that of TprC from EGF-stimulated cells (data not shown).
Peptide maps obtained for TprC from UO126-treated cells and
for TprC-M4 were identical (Fig. 5B). This implies that the
effect of UO126 pretreatment of cells is similar to the effect of
mutating all the phosphorylation sites of Tpr (TprC-M4 mu-
tant). These results provide compelling evidence that ERK2
phosphorylates TprFL and TprC in vivo on the same target
sites that were mapped in vitro.
Tpr-ERK2 interaction requires ERK2 phosphorylation and
dimerization but not the D domain. Because Tpr bound only to
activated ERKs, we examined the molecular mechanism by
which ERK activation enabled Tpr binding. In the inactive
state, ERKs are anchored to MEKs in the cytoplasm. Follow-
ing cell stimulation and activation, ERKs are reported to
dimerize and migrate into the nucleus (22). To decipher the
structural and functional requirements of ERK in mediating
the Tpr-ERK interaction, we utilized well-characterized ERK2
mutants. Endogenous Tpr coimmunoprecipitated efficiently
with wild-type ERK2 following activation but not with the
phosphorylation site mutant ERK2-TAYF (Fig. 6A). Since
phosphorylation of ERK2 is a prerequisite for dimerization, we
asked whether ERK2 dimerization is essential for Tpr binding.
While Tpr coimmunoprecipitated with activated wild-type
ERK2, no interaction was detectable with the ERK2 dimer-
FIG. 4. Tpr is phosphorylated by ERK2 at four different sites. (A) COS-1 cells were transfected with FLAG-TprFL, FLAG-TprC, and
FLAG-TprC mutants (as specified above the maps). The immunoprecipitated FLAG-tagged Tpr proteins were mixed with immunoprecipitated
FLAG-ERK2, and kinase reactions were carried out with [-32P]ATP. In vitro-phosphorylated FLAG-tagged TprFL, TprC, and TprC mutants
were digested with trypsin, and the resulting phosphopeptides were mapped by two-dimensional separation on TLC. Spots in similar positions in
TprFL and TprC maps are indicated by numbered black arrows. Spots missing due to mutations in the TprC phosphorylation sites are indicated
by numbered white arrows. (B) The upper panel depicts the nomenclature of the combination target site mutants of TprC. The putative D domain
(2091RRQSVGRGLQL2101) and DEF motif (2150FRF2152) are also indicated (residues that match the consensus for each motif are indicated by
bold). In vitro-phosphorylated proteins were digested with trypsin, and the resulting phosphopeptides were mapped by TLC (4). Major (spots 3,
4, and 4*) and minor (spots 1 and 2) spots in TprC are indicated by numbered black arrows. Missing spots in TprCM2, TprC16M3, and TprC12M3
are indicated by numbered white arrows. In TprC-M4, the location of the missing spots is circled by a dotted line. (C) Incorporation of 32P in in
vitro-phosphorylated TprC, TprC-M4, and the vector control samples was quantified by Cerenkov counting in three independent experiments.
Counts in TprC were normalized to 100% in each experiment, and the percent counts in other samples were calculated with respect to TprC. The
results were plotted with percent counts with respect to TprC on the y axis and the samples on the x axis.
FIG. 5. ERK2 phosphorylates Tpr at the same sites in vivo and in
vitro. (A) COS-1 cells were transfected with FLAG-TprFL or FLAG-
TprC vectors. Transfected cells were labeled metabolically for 3 h. For the
EGF-stimulated samples, EGF (20 ng/ml) was added after 3 h to the
labeling cells for 10 min. For samples with MEK inhibitor UO126, 20 M
of inhibitor was present during the 3-h labeling and EGF stimulation.
FLAG-tagged TprFL and TprC were immunoprecipitated, resolved,
transferred, and autoradiographed. In vivo-labeled TprFL and TprC were
digested with trypsin, and the resulting phosphopeptides were mapped by
two-dimensional TLC. In vitro-labeled TprC from the earlier experiment
was resolved on TLC plates along with in vivo-labeled TprC and TprFL.
Peptide spots that show slight increases in intensity following EGF stim-
ulation are indicated by white arrows (panel 2). Spots that did not disap-
pear with UO126 pretreatment are marked in the first panel by a dotted
line. (B) FLAG-TprC- and FLAG-TprC-M4-transfected cells were met-
abolically labeled as described above with EGF stimulation. Tryptic di-
gested peptides were resolved by two-dimensional TLC (4).
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ization mutant FLAG-ERK2-4 (Fig. 6B). These results
demonstrate that Tpr-ERK2 interaction requires both phos-
phorylation of ERK2 (on TEY residues) and its dimerization.
The Tpr sequences required for ERK interaction were inves-
tigated next. The known ERK2-interacting proteins associate with
ERK2 through either a KIM (D domain) or a docking domain
(DEF motif) or both. Putative D domain (2091RRX6LXL
2101)
and DEF motif (2150FXF2152) sequences are found in the C-
terminal region. Mutating D316 and D319 in ERK2 is reported to
abolish association with proteins containing a D domain (42).
However, these mutations did not affect the interaction with Tpr;
but they did abolish interaction with two other known binding
proteins, MEK1 and Rsk1, as reported in the literature (42)
(Fig. 6C).
ERK2 interacts with Tpr through DEF and phosphorylation
sites. Next, we investigated whether ERK associates with Tpr
through a DEF motif. It has been shown that the phosphory-
lation of T183 and Y185 residues on ERK2 causes a confor-
mational change that results in the interaction of pY185,
M197, L198, Y231, and L232 residues on the ERK2 surface,
with two phenylalanine residues in the DEF motif-containing
peptides (24). We found that ERK2 mutated at L232 did not
associate with TprC (Fig. 7A), and conversely, TprC with a
mutated DEF domain (FXF3AXA) showed decreased asso-
ciation with ERK2 (Fig. 7C; 	50%). These data strongly sug-
gest that the interaction of ERK2 with Tpr occurs via the DEF
domain on Tpr. However, to our surprise, we also detected
decreased interaction of TprC-M4 with ERK2 compared to
that of the wild type (Fig. 7B and C; 	60%). These results
were intriguing, as they suggested that ERK phosphorylation
sites in Tpr might be involved in the ERK-Tpr binding inter-
action. To further investigate this observation, we generated
two more Tpr mutants: FLAG-TprC-FXF3AXA,M4, a com-
bination mutant of phosphorylation sites and DEF mutations,
and FLAG-TprC-60, a deletion of 60 amino acids encom-
passing DEF and two major and one minor phosphorylation
sites. Significantly, when we utilized a combination mutant of
docking domain and phosphorylation sites (TprC-FXF3
AXA,M4) or a TprC-60 mutant, we could barely detect any
interaction between Tpr and ERK2 (Fig. 7B and C; 	5%).
These results show that the interaction between ERK2 and Tpr
is through the mutually reinforcing combination of the DEF
motif and the Tpr phosphorylation sites.
ERK2 interaction with Tpr is enhanced by phosphorylation.
Our results strongly suggested that the target phosphorylation
sites and DEF domain in Tpr cooperate in enhancing its in-
teraction with ERK2. The interaction of target phosphoryla-
tion sites on Tpr with ERK2 could be mediated through the
hydroxyl groups on serine/threonine residues, or alternatively,
the interaction could be mediated through the phosphorylated
serine/threonine residues. In order to distinguish between
these possibilities, we looked at the interaction of HA-ERK2
and the kinase-inactive HA-ERK2-K52R (33) with FLAG-
TprC and FLAG-TprC-FXF3AXA (Fig. 8). Though ERK2-
K52R has very low kinase activity, it is efficiently phosphory-
lated on TEY residues (20), which is necessary for ERK2-Tpr
interaction. If the interaction is through the DEF and the
hydroxyl groups of target serine/threonine residues, there
should not be any difference in the binding efficiencies of TprC
with activated ERK2 and ERK2-K52R. Furthermore, this
∆
FIG. 6. Tpr-ERK2 interaction requires ERK2 phosphorylation and dimerization, but not the D domain. (A) Cells transfected with pcDNA3,
FLAG-ERK2, and the FLAG-ERK2-TAYF mutant were serum starved and stimulated with EGF. Proteins immunoprecipitated (IP) with
FLAG-M2 agarose beads from lysed cells were immunoblotted and probed with anti-FLAG and anti-Tpr antibodies. (B) Cells transfected with
pcDNA3, FLAG-ERK2, and the FLAG-ERK2-4 dimerization mutant were serum starved and stimulated with EGF. Proteins immunoprecipi-
tated with FLAG-M2 agarose beads were immunoblotted and probed with anti-FLAG and anti-Tpr antibodies. (C) COS-1 cells transfected with
pcDNA3, FLAG-ERK2, and FLAG-ERK2-DD3NN were serum starved, followed by stimulation with EGF as usual. Proteins immunoprecipi-
tated from lysed cells with -FLAG-M2 agarose beads were immunoblotted, and lysates and immunoprecipitates were probed with anti-FLAG and
anti-MEK1 mouse monoclonal (Transduction Laboratories), anti-Rsk1 goat polyclonal (Santa Cruz Biotechnology Inc.), and anti-Tpr antibodies.
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FIG. 7. ERK2 interacts with Tpr through DEF and phosphorylation sites. (A) Cells were cotransfected with FLAG-ERK2 or FLAG-ERK2-
DD3NN or FLAG-ERK2 L232A or pcDNA3 and HA-TprC. Following serum starvation and EGF stimulation, proteins were immunoprecipi-
tated (IP) with anti-FLAG antibodies. Lysates and immunoprecipitated proteins were probed with anti-FLAG and anti-HA antibodies. Immu-
noprecipitates were also probed with -phospho-ERK antibodies. (B) Cells were transfected with FLAG-TprC or HA-ERK2 or double transfected
with FLAG-TprC or FLAG-TprC-FXF3AXA, FLAG-TprC-M4, or FLAG-TprC-FXF3AXA,M4 or FLAG-TprC-60 and HA-ERK2. Follow-
ing serum starvation and EGF stimulation, proteins were immunoprecipitated with anti-HA antibodies. Lysates and immunoprecipitated proteins
were probed with anti-FLAG, anti-HA, and anti-phospho-ERK antibodies. (C) Appropriate enhanced chemiluminescence exposures that are
within the linear range of the X-ray film were used for quantitating coimmunoprecipitated wild-type and Tpr mutants using Image J software
(Wayne Rasband, National Institutes of Health). Presence () or absence () of EGF and the sample names are indicated. Values obtained for
the TprCEGF sample were set at 100%. Percent binding values for the remaining samples were calculated with respect to TprCEGF in each
experiment. Percent binding values from three independent experiments were used for calculating standard deviations.
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model also predicts that ERK2 and ERK2-K52R will associate
equally well with TprC-FXF3AXA, where the DEF motif is
mutated. However, if the phosphorylation of target serine/
threonine residues is required for the interaction, one would
expect decreased interactions of TprC with ERK2-K52R com-
pared with those for ERK2. Since ERK2-K52R does not pos-
sess kinase activity, its interaction with TprC should be similar
to that of the ERK2 interaction with TprC-M4. Results ob-
tained in Fig. 8 agree well with this prediction. Likewise,
ERK2-K52R interaction with TprC-FXF3AXA should be
similar to that of ERK2 with TprC-FXF3AXA,M4. It is evi-
dent from the data (Fig. 8) that the TprC-FXF3AXA inter-
action with ERK2-K52R is almost negligible. These results
suggest that the interaction of ERK2 with Tpr is through DEF
and that the phosphorylated serine/threonine residues and the
phosphorylation of Tpr by ERK2 increase their interaction.
ERK2 phosphorylates proteins that interact with Tpr. The
fact that the ERK-Tpr interaction is stabilized by phosphory-
lation of serine/threonine residues suggests that Tpr provides a
stable docking site for active ERK2. This would allow the
active ERK2 to be tethered to the nuclear pore and phosphor-
ylate other proteins in trans, including proteins that are tran-
siting the nuclear pore. To test this hypothesis, we looked for
ERK substrates in immunoprecipitates of Tpr. COS-1 cells
were cotransfected with HA-ERK2 or HA-ERK2-QG and
FLAG-TprFL or the TprFL-FXF3AXA,M4 mutant. As an-
ticipated, ERK2 or ERK2-QG coimmunoprecipitated with the
wild-type TprFL but not with the mutant TprFL-FXF3
AXA,M4 (Fig. 9A), which is in agreement with our results in
Fig. 7B. To detect substrates of Tpr-associated ERK2, we
performed in vitro kinase reactions with these immunoprecipi-
tates, using the ATP analog [-32P]cpATP. Since [-32P]
cpATP is selectively utilized by ERK2-QG, the direct ERK2
substrates will become radiolabeled in immunoprecipitates
that contain ERK2-QG and wild-type Tpr but not in those that
contain wild-type ERK2 (which cannot utilize the analog) nor
in immunoprecipitates of Tpr FXF3AXA,M4. As Tpr is a
substrate for ERK2, we detected significant phosphorylation of
Tpr by ERK2-QG (Fig. 9B). In addition, we detected another
radiolabeled band at 	70 kDa (Fig. 9B), indicating phosphor-
ylation of an additional Tpr-interacting protein by the Tpr-
bound active ERK2. Moreover, when the resolution of the gel
system was increased by using two-dimensional gels, we de-
tected more spots indicative of direct phosphorylations by Tpr-
tethered ERK2 (Fig. 9C, middle panel). These data suggest
that ER2K phosphorylated the proteins that interact with Tpr
and that the ERK2-Tpr association is necessary for this pro-
cess.
Tpr regulates YFP-ERK2 recruitment into the nucleus in
response to EGF treatment. In addition to Tpr, previous re-
ports have shown that ERK associates with other components
of the nuclear pore complex, nucleoporins Nup153 and
Nup214. These findings suggested that ERK binding to nuclear
pore complex proteins could facilitate the translocation of ac-
tivated ERK2 from the cytoplasm to the nucleus (26, 46). We
thus tested whether Tpr plays any role in nuclear transport of
ERKs by depleting the cells of Tpr using double-stranded
siRNA. We could effectively deplete the cells of Tpr protein
(Fig. 10A), and they remained depleted until 96 h (data not
shown). Tpr siRNA-treated HEK293T cells previously trans-
fected with CFP-MEK1 and YFP-ERK2 were serum starved,
followed by EGF stimulation. Localization of YFP-ERK2 in
the nucleus before and after EGF stimulation was monitored
by fluorescence microscopy. As shown in Fig. 10B, Tpr atten-
uation resulted in decreased recruitment of YFP-ERK2 into
the nucleus. In addition, we observed that overexpression of
full-length Tpr led to decreased translocation of YFP-ERK2 to
the nucleus in response to EGF stimulation (Fig. 10C). This
could be due to sequestration of YFP-ERK2 by overexpressed
Tpr or due to sequestration of other proteins that may be
required for ERK2 translocation, thus decreasing the nuclear
levels of ERK2. Based on these data, we deduce that either
attenuation or overexpression of Tpr blocks YFP-ERK2 local-
ization to the nucleus. Collectively, our data demonstrate that
Tpr plays a role in modulating the translocation of activated
ERK2 from the cytoplasm to the nucleus and that this regu-
lation is dependent on the amount of Tpr present in the cells.
DISCUSSION
In this study, we present evidence that Tpr is a bona fide
ERK2 substrate in vivo. We have shown that Tpr is a direct
substrate for ERK2 in cell lysates and in vitro, that the sites of
in vitro phosphorylation by MAPK are identical to a subset of
in vivo phosphorylation sites, and that these specific phosphor-
ylations disappeared after blockade of the MAPK ERK2 path-
way. We also show that ERK2 binds to Tpr and have identified
both the docking domains on Tpr and the complementary
domain on ERK2. We show that phosphorylation of Tpr by
ERK stabilizes the interaction between these proteins and that
this interaction positions ERK2 for phosphorylation of other
substrates. Finally, we provide evidence that the ERK-Tpr
interaction regulates nuclear translocation of ERK2. Collec-
tively, the findings develop a picture of activated ERK2 inter-
acting with Tpr to enhance its nuclear uptake and to phosphor-
ylate other proteins that either are transiting through the pore
or may be involved in nuclear pore function.
Tpr-ERK2 interaction motifs. The D and DEF domains are
structural elements important for efficient interaction of di-
verse sets of proteins with MAPKs (41, 44). The D domain
associates promiscuously with MAPK family members, includ-
ing ERK, JNK, and p38 (42, 43). On the other hand, the FXF
FIG. 8. Tpr phosphorylation enhances ERK2-Tpr binding. (A) Cells
were cotransfected with pcDNA3 or HA-ERK2 or HA-ERK2-K52R and
FLAG-TprC or FLAG-TprC-FXF3AXA. Following serum starvation
and EGF stimulation, proteins were immunoprecipitated (IP) with
anti-HA beads (Sigma). Lysates and immunoprecipitated proteins were
probed with anti-FLAG and anti-HA antibodies.
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motif of the DEF domain specifically associates with ERK and
does not mediate the interaction with JNK and p38, probably
due to steric constraints in JNK and p38 (21, 24, 47). Our
observation that Tpr interacts with ERK primarily through the
FXF motif of the DEF domain suggested that Tpr would
specifically associate with ERKs. Indeed, Tpr associated spe-
cifically with ERK2 and ERK1 but not with the close family
member JNK1 or p38 or the ERK upstream activator MEK1
(Fig. 2). Structural and biochemical studies showed that ERK
preferentially phosphorylates residues that are located close to
the N terminus of the DEF domain (11, 21, 24). Consistent
with this, we found that the major Tpr phosphorylation sites
are located N terminally of the DEF domain. Moreover, be-
cause kinase-defective ERK2-K52R is less effective at binding
FIG. 9. ERK2 phosphorylates proteins that interact with Tpr. (A) COS-1 cells were cotransfected with FLAG-TprFL or FLAG-TprFL-
FXF3AXA,M4 and HA-ERK2 or HA-ERK2-QG. Cells were serum starved and stimulated with 20 ng/ml EGF, and the proteins were
immunoprecipitated (IP) with FLAG-M2 agarose beads. In vitro kinase reactions were carried out with 1/10 of the immunoprecipitated proteins,
and part of the lysate was resolved by SDS-PAGE, transferred onto a nitrocellulose membrane, and probed with anti-FLAG and anti-HA
antibodies. (B) Kinase reactions were carried out with the remaining 9/10 of immunoprecipitated proteins by using 	20 Ci [-32P]cpATP (analog
ATP) as the substrate for 15 min at 30°C. One-fifth of the volume of these reaction mixtures was resolved by SDS-PAGE, transferred onto a
nitrocellulose membrane, and autoradiographed. (C) The remaining part of the kinase reaction mixtures was resolved on pH 4 to 7 two-
dimensional gels as described in our previous report (10). Background spots indicated by white arrows were used for aligning the autoradiograms.
Additional spots that are specifically detected in TprFLERK2-QG reactions (middle panel) are indicated by black arrows.
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than the wild-type ERK2, it is likely that the phosphorylation
of Tpr occurs in cis by the kinase molecule that is bound to the
Tpr. Together, these data indicate that the DEF domain of Tpr
has a dual function, as it specifically selects ERK and directs
ERK activity toward specific phosphorylation sites on Tpr.
Tpr functions. Nucleoporin Tpr was reported to play a role
in the export of leucine-rich nuclear export signal-containing
proteins (14). In order to investigate the role of ERK-mediated
phosphorylation of Tpr on the import/export of proteins, we
utilized a hormone-inducible, GFP-labeled chimeric Rev pro-
tein (Rev/GR/GFP) construct developed by Love et al. (25).
We did not detect any significant difference in the import or
export of the Rev/GR/GFP protein between wild-type and
Tpr-depleted COS-1 cells (data not shown). In agreement with
these findings, Shibata et al. (39) reported that depleting nuclei
of Tpr by microinjection with Tpr antibody did not alter either
protein import or export. Contrasting results obtained by
Frosst et al. (14) and our group could be due to differences in
the types of cell lines and the fact that they used antibody
injection whereas we used siRNA as a mechanism for deplet-
ing Tpr (data not shown).
The yeast homolog Mlp1 was shown to be involved in the
nuclear retention of unspliced mRNAs (16). These data imply
a possible role for Tpr in the export of unspliced mRNA.
Knockdown of Tpr with siRNA resulted in increased export of
unspliced RNA as measured by production of the HIV gag
gene product p24 in the supernatant (J. Coyle, D. Rekosh, and
M.-L. Hammarskjold, personal communication). We hypothe-
sized that ERK binding and phosphorylation could alter this
measurable Tpr function, but experiments carried out by us in
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FIG. 10. Tpr regulates YFP-ERK recruitment into the nucleus in response to EGF stimulation. Control- or Tpr siRNA-treated HEK293T cells
expressing CFP-MEK and YFP-ERK were plated on glass dishes coated with extracellular matrix components (10 g/ml fibronectin and 5 g/ml
collagen type IV). The next day, cells were serum deprived for 3 h and stimulated with EGF (10 ng/ml). (A) Western blot analysis of Tpr expression
in control and Tpr siRNA-treated cells. Lysates from control and Tpr knockdown cells were probed with antiTpr and antipaxillin antibody as
described in Materials and Methods. (B) Images of and quantification of YFP-ERK nuclear localization in control and Tpr siRNA-treated
HEK293T cells prior to and after EGF stimulation. (C) Images show the quantification of YFP-ERK in pcDNA3- or Flag-Tpr-expressing cells
prior to and after EGF stimulation and Western blot analysis of Flag-Tpr expression in pcDNA3- and Flag-Tpr-expressing cells. In panels B and
C, approximately 50 to 70 cells per each experimental condition were used to quantify YFP-ERK translocation to the nucleus. Each experiment
was repeated twice.
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collaboration with Coyle et al. did not provide evidence that
ERK2-mediated phosphorylation of Tpr plays a role in the
export of unspliced mRNAs (data not shown).
Role of Tpr-ERK2 interaction. ERK binding could play a
role in the localization of Tpr to the nuclear pore, as has been
observed in the case of the cyclin-dependent kinase inhibitor
p27kip1 (13) and NFATc (nuclear factor of activated T cells)
(31). However, expression of Tpr-M4, which associates poorly
with ERK2 and cannot be phosphorylated by it, localized nor-
mally in the nuclear membrane as judged by immunofluores-
cence (Fig. 11). Previous studies implicated ERK2 interaction
with nucleoporins Nup153 and -214 in the translocation of
both unphosphorylated and phosphorylated ERK2 (26, 46).
Mutants of ERK2 defective in interaction with the FXF motif
of DEF domain-containing proteins show decreased rates of
nuclear import. This was proposed to be due to the decreased
interaction of mutant ERK2 protein with nucleoporin Nup153
(48). However, translocation of wild-type and mutant GFP-
ERK2 in Nup153-depleted cells was not measured. Since the
interaction of ERK2 with Tpr is through the DEF domain, we
speculated that Tpr might play a role in modulating the trans-
location of ERK2 into the nucleus. In agreement with these
predictions, depletion or overexpression of Tpr resulted in
decreased localization of ERK2 upon EGF stimulation (Fig.
10). The fact that either depletion or overexpression of Tpr
interfered with ERK translocation is consistent with our pro-
posal that Tpr functions both as an ERK substrate and as an
ERK scaffold: it is characteristic of scaffold proteins that ap-
propriate stoichiometry of all the components is necessary for
accurate function (35).
Our finding that the DEF domain and phosphorylation of
Tpr mutually enhance the Tpr-ERK interaction was surprising,
and it raises questions as to the role such a positive feedback
might play in cell function. Some of the best-characterized
ERK substrates decrease their association with ERK after they
are phosphorylated (e.g., p90RSK; see Fig. 6C and reference
34). This allows the substrate to move to its site of action and
for the activated ERK to service several substrate proteins,
thus amplifying the signaling cascade. However, stable associ-
ation between substrate and kinase suggests that Tpr serves
both as a substrate and as a scaffold. This would allow the
active ERK2 to be tethered to the nuclear pore and to phos-
phorylate various proteins that are transiting the nuclear pore.
A similar concept has recently been proposed by Pokholok et
al. (30), who reported that yeast MAPKs stably associate with
appropriate specific gene promoters and phosphorylate multi-
ple components of the transcription machinery. An analogous
premise was previously suggested for ERK recruitment by the
Fos transcription factor through its DEF domain, which was
required for Fos phosphorylation. This interaction through the
DEF domain was proposed to have wider functional implica-
tions that include transphosphorylation of proteins associated
with Fos in the AP1 transcription complex (27). Consistent
with these concepts, we found that the ERK2-QG “pocket”
mutant specifically phosphorylated proteins that interact with
Tpr (Fig. 9). The low levels of these proteins precluded their
identification in these experiments, but future studies that
identify the substrates of Tpr-bound ERK should provide in-
sight into the ways that the substrate and scaffold functions of
Tpr interact in nuclear transport.
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